Gri Bio, INC. 8-K Filing
Ticker: GRI · Form: 8-K · Filed: Dec 2, 2025 · CIK: 1824293
Sentiment: neutral
Filing Stats: 656 words · 3 min read · ~2 pages · Grade level 14.4 · Accepted 2025-12-02 08:00:54
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share GRI The Nasdaq Capital Mark
- $35,000,000 — value of listed securities of less than $35,000,000 and annual net income of less than $500
- $500,000 m — ,000 and annual net income of less than $500,000 maintain stockholders' equity of at least
- $2,500,000 — intain stockholders' equity of at least $2,500,000 (the "Stockholders' Equity Requirement"
Filing Documents
- val-20251126.htm (8-K) — 22KB
- val-20251126_g1.jpg (GRAPHIC) — 16KB
- val-20251126_g2.jpg (GRAPHIC) — 2KB
- 0001824293-25-000155.txt ( ) — 168KB
- val-20251126.xsd (EX-101.SCH) — 2KB
- val-20251126_lab.xml (EX-101.LAB) — 23KB
- val-20251126_pre.xml (EX-101.PRE) — 13KB
- val-20251126_htm.xml (XML) — 3KB
01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 26, 2025, the Company received a letter from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with the minimum stockholders' equity requirement for continued listing on The Nasdaq Capital Market (the "Notice") based on the information provided in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025. Nasdaq Listing Rule 5550(b)(1) requires that companies listed on The Nasdaq Capital Market with a market value of listed securities of less than $35,000,000 and annual net income of less than $500,000 maintain stockholders' equity of at least $2,500,000 (the "Stockholders' Equity Requirement"). In accordance with Nasdaq rules, the Company was provided 45 calendar days, or until January 10, 2026, to submit a plan to regain compliance with the Stockholders' Equity Requirement (the "Compliance Plan"). The Company plans to submit a Compliance Plan. If the Compliance Plan is determined to be acceptable to the Staff, the Staff would have the discretion to grant the Company an extension of 180 calendar days from the date of the Notice to regain compliance with the Stockholders' Equity Requirement. There can be no assurance that the Compliance Plan will be accepted or that, if it is, the Company will be able to regain compliance. The Notice has no immediate effect on the Company's continued listing on The Nasdaq Capital Market, subject to the Company's compliance with other continued listing requirements. If the Staff does not accept the Compliance Plan, the Staff will provide written notification to the Company that the Compliance Plan has been rejected and that the Common Stock is subject to delisting. At that time, the Company may appeal the Staff's determination to a Nasdaq Hearing Panel.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 2, 2025 GRI BIO, INC. By: /s/ Leanne Kelly Name: Leanne Kelly Title: Chief Financial Officer